Which prescription drugs have dangerous interactions with methylene blue?
This fact-check may be outdated. Consider refreshing it to get the most current information.
Executive summary
Methylene blue causes dangerous interactions chiefly by inhibiting monoamine oxidase A (MAO‑A), risking serotonin syndrome when combined with serotonergic drugs (SSRIs, SNRIs, TCAs, some opioids, triptans and other SRIs) and is contraindicated with many antidepressants and certain opioids [1] [2] [3]. Multiple clinical and regulatory sources list dozens to hundreds of interacting medicines — Drugs.com reports 198 interacting drugs and prescribing information warns to avoid SSRIs, SNRIs, MAOIs and opioids [4] [3] [2].
1. Why this interaction is dangerous: the MAO‑A mechanism and serotonin syndrome
Methylene blue inhibits monoamine oxidase A, the enzyme that breaks down serotonin; when given to patients already taking serotonergic medications, serotonin can accumulate and precipitate serotonin syndrome — a potentially fatal constellation of fever, rigidity, hyperreflexia, altered mental status and autonomic instability — a risk flagged by the FDA and professional reviews [1] [5] [6].
2. Which drug classes are singled out by regulators and labels
Regulatory labels and prescribing information advise avoiding methylene blue with selective serotonin reuptake inhibitors (SSRIs), serotonin‑norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), norepinephrine‑dopamine reuptake inhibitors (NDRIs), triptans and certain opioids because of possible fatal serotonin toxicity [2] [3] [1].
3. Examples of specific drugs reported to interact
Public drug databases and case reports list common antidepressants and some opioids as problematic. Drugs.com and the FDA highlight SSRIs/SNRIs such as sertraline and venlafaxine; case reports document severe reactions after methylene blue was given to a patient on venlafaxine [4] [7] [8] [1]. Medscape prescribing notes cite hydrocodone and other opioids as having increased toxicity when combined with methylene blue [9].
4. Scope and scale: many interacting agents, but lists vary
Interaction-checkers differ in tally: Drugs.com reports 198 interacting medications; other references say dozens to hundreds, and package inserts explicitly warn against combinations with SRIs and opioids [4] [3] [2]. Discrepancies arise because some sources count off‑target or theoretical interactions, while regulators emphasize clinically dangerous combinations [10] [6].
5. Clinical context matters: route, dose and urgency change guidance
Reviews note most clear reports of severe serotonin toxicity involve intravenous methylene blue or higher doses; some clinical sources say the contraindication largely rests on IV use and extrapolation from MAOI pharmacology, which matters when clinicians must decide in emergencies [6] [5]. The prescribing information nonetheless instructs clinicians to stop serotonergic drugs prior to methylene blue when possible [2] [3].
6. Opioids and other non‑antidepressant risks
Beyond classic antidepressants, some opioids (eg, hydrocodone, tramadol, certain fentanyl preparations) can precipitate serotonin toxicity when combined with MAO inhibition; Medscape and the package insert warn opioids may interact to cause serotonin syndrome or increased opioid toxicity including respiratory depression [9] [3].
7. What clinicians and patients are advised to do
Labels and safety communications recommend avoiding concomitant use, stopping serotonergic drugs before methylene blue when feasible, and monitoring for serotonin syndrome if co‑administration is unavoidable; the FDA and prescribing information also advise a waiting interval after methylene blue before restarting serotonergic drugs [1] [3] [2].
8. Limitations, disagreements and gaps in the record
Available sources show consensus about the serotonin‑related danger but differ on the absolute list and the clinical magnitude for low‑dose or non‑IV use: some pharmacy reviews emphasize the IV context and extrapolation [6], while interaction checkers count many theoretical interactions [4] [10]. Available sources do not mention a single universally agreed numeric cutoff dose or an agreed safe interval for every drug class beyond label recommendations (not found in current reporting).
9. Bottom line for patients and prescribers
Treat methylene blue as a potent MAO‑A inhibitor: assume high risk with SSRIs, SNRIs, TCAs, MAOIs, many triptans and certain opioids, follow FDA and product‑label guidance to avoid combinations or stop serotonergic agents when possible, and monitor urgently for serotonin syndrome if exposure occurs [1] [2] [3]. For specific drug‑by‑drug decisions, consult up‑to‑date interaction tools and the methylene blue prescribing information cited above [4] [3].
Sources cited: FDA drug safety communication, Drugs.com interaction pages and consumer materials, package insert/DailyMed, StatPearls, Medscape, Poison.org, and clinical reviews [1] [4] [8] [2] [5] [9] [7] [6].